EN
Clarification Statement
SINOVAC Biotech Ltd. ("SINOVAC") recently noticed a Portuguese-language press release with a statement that does not conform to the facts. This fraudulent statement ("Fraudulent Statement") was published by certain media outlets in Brazil on 16 July 2021, claiming that "the World Brands S.A. and individuals can purchase from SINOVAC Biotech Ltd." which was fake. Several media have reported about the Fraudulent Statement.
With regard to this, we hereby clarify that:
(i) the Covid-19 vaccine (CoronaVac®) is developed, manufactured and distributed by SINOVAC Life Sciences Co., Ltd.
(ii) In Brazil, only the Instituto Butantan, our exclusive partner, can purchase CoronaVac®. We have been working hard with the Instituto Butantan to provide affordable vaccines to the Brazilian people.
(iii) Any information released by any company without authorization from SINOVAC has no legal significance.
(iv) For illegal acts of publishing fake news, we reserve the right to take all actions, including taking legal actions, seeking remedies and seeking accountability.
SINOVAC Biotech Ltd.
Jul 17, 2021
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com